8-K: Fortress Biotech Q3 2025: Revenue Up, Net Income Positive

Fortress Biotech reports a 20.5% increase in Q3 2025 net revenue to $17.6 million, achieving a net income of $3.7 million, driven by strategic divestitures and product launches.

Summary

• Consolidated net revenue for the third quarter ended September 30, 2025, totaled $17.6 million, representing a 20.5% increase compared to $14.6 million for the third quarter of 2024.
• Consolidated net income attributable to common stockholders was $3.7 million, or $0.13 per share basic and $0.11 per share diluted, for Q3 2025, a significant improvement from a net loss of $(15.0) million, or $(0.76) per share basic and diluted, for Q3 2024.
• Consolidated cash and cash equivalents totaled $86.2 million as of September 30, 2025, an increase of $28.9 million year-to-date from $57.3 million as of December 31, 2024.
• Fortress subsidiary Checkpoint Therapeutics was acquired by Sun Pharma in May 2025, with Fortress receiving approximately $28 million upfront and eligible for up to an additional $4.8 million under a contingent value right (CVR), plus a 2.5% royalty on future net sales of UNLOXCYT (cosibelimab-ipdl).
• Avenue Therapeutics, a Fortress subsidiary, announced the acquisition of its subsidiary Baergic by Axsome Therapeutics in November 2025, with Avenue eligible for a $0.3 million upfront payment (less transaction expenses), up to $2.5 million in development/regulatory milestones for the first indication, $1.5 million for each subsequent indication, up to $79 million in sales-based milestones, and a tiered mid-to-high single-digit royalty on potential global net sales of AXS-17 (formerly BAER-101).
• Dotinurad, a next-generation URAT1 inhibitor for gout, is advancing in two Phase 3 clinical trials, following Crystalys Therapeutics' $205 million Series A financing; Urica Therapeutics (a majority-owned Fortress subsidiary) is eligible to receive a 3% royalty on future net sales of dotinurad.
• Journey Medical Corporation's Emrosi (rosacea treatment) demonstrated superior efficacy in pooled Phase 3 data analysis and achieved expanded payer access covering over 100 million commercial lives in the United States.
• The FDA issued a Complete Response Letter (CRL) for the New Drug Application (NDA) for CUTX-101 (copper histidinate) for Menkes disease on September 30, 2025, citing cGMP deficiencies at the manufacturing facility, though no efficacy or safety concerns were identified; Sentynl expects to resubmit the NDA shortly.
• AstraZeneca's anselamimab (AL amyloidosis) Phase III CARES clinical program did not achieve statistical significance for its primary endpoint but showed clinically meaningful improvement in a prespecified subgroup, which AstraZeneca plans to submit to regulatory authorities.
• Mustang Bio's MB-101 (IL13Ra2-targeted CAR T-cells) received Orphan Drug Designation from the FDA for the treatment of recurrent diffuse and anaplastic astrocytoma and glioblastoma.

Sentiment

Score: 8

Explanation: The company reported a strong financial turnaround with positive net income and increased revenue, driven by successful monetization of assets and operational efficiency. While there was a regulatory delay for one product, the overall strategic progress and pipeline advancements are positive.

Positives

• Achieved consolidated net income attributable to common stockholders of $3.7 million in Q3 2025, a substantial improvement from a $(15.0) million net loss in Q3 2024.
• Total net revenue increased by 20.5% to $17.6 million for Q3 2025 compared to Q3 2024.
• Consolidated cash and cash equivalents increased by $28.9 million year-to-date, reaching $86.2 million as of September 30, 2025.
• Successfully monetized Checkpoint Therapeutics, generating approximately $28 million upfront and potential for additional CVR payments (up to $4.8 million) and a 2.5% royalty on UNLOXCYT sales.
• Strategic exit of Baergic Bio, with Avenue (a Fortress subsidiary) eligible for upfront, milestone, and royalty payments.
• Dotinurad (gout treatment) is advancing in two Phase 3 trials, supported by Crystalys Therapeutics' $205 million Series A financing, with Urica (a Fortress subsidiary) retaining a 3% royalty on future net sales.
• Journey Medical's Emrosi launch success, expanded payer access to over 100 million commercial lives, and demonstrated superior efficacy in Phase 3 pooled analysis.
• Consolidated research and development expenses significantly decreased to $0.2 million in Q3 2025 from $9.4 million in Q3 2024.
• Consolidated selling, general and administrative costs decreased to $17.4 million in Q3 2025 from $22.0 million in Q3 2024.
• Mustang Bio's MB-101 received broader Orphan Drug Designation for recurrent diffuse and anaplastic astrocytoma and glioblastoma.

Negatives

• The FDA issued a Complete Response Letter (CRL) for CUTX-101 due to cGMP deficiencies at the manufacturing facility, delaying its potential approval.
• AstraZeneca's anselamimab Phase III CARES program for AL amyloidosis did not achieve statistical significance for its primary endpoint.

Risks

• Uncertainty related to the timing and amounts expected to be realized from future milestone, contingent value right, royalty or similar future revenue streams, if at all.
• Risks relating to the ability to identify, acquire, close and integrate product candidates successfully and on a timely basis.
• Uncertainties relating to preclinical and clinical testing.
• Ability to obtain regulatory approval for products under development.
• Ability to successfully commercialize products for which regulatory approval is received or receive royalties or other distributions from third parties.
• Ability to secure and maintain third-party manufacturing, marketing, and distribution of products and product candidates.
• Government regulation.
• Patent and intellectual property matters.
• Competition.
• Need for substantial additional funds and uncertainties relating to financings.

Future Outlook

Fortress Biotech plans to continue disciplined execution, optimize capital allocation, and advance high-impact assets. Sentynl expects to resubmit the NDA for CUTX-101 shortly. AstraZeneca plans to submit prespecified subgroup analysis from the CARES trials for anselamimab with regulatory authorities. Fortress intends to advance MB-101 in combination with MB-108 as a potential treatment option.

Management Comments

• "Fortress has achieved several strategic milestones that reinforce the strength of our diversified business model and our continued ability to enhance shareholder value across our portfolio."
• "The acquisition of two subsidiaries this year, Checkpoint Therapeutics, Inc. (Checkpoint), by Sun Pharma and Baergic Bio, Inc. (Baergic) by Axsome Therapeutics (Axsome), are both strategic exits that represent validation of our approach."
• "We also anticipate the resubmission of the New Drug Application (NDA) for CUTX-101, which, upon approval, may qualify for a Priority Review Voucher further demonstrating the potential embedded value in our pipeline."
• "Journey Medical Corporation (Journey Medical) continues to deliver strong operational execution, highlighted by the successful launch of Emrosi and accelerating commercial performance, supported by expanded payer coverage and new pooled Phase 3 data analysis presented at Fall Clinical demonstrating Emrosis statistical and clinical superiority over Oracea and placebo for the treatment of rosacea."
• "The $205 million Series A financing announced by Crystalys Therapeutics, Inc. (Crystalys) underscores the markets confidence in dotinurads best-in-class potential for safety and efficacy."
• "As we move forward, Fortress remains focused on disciplined execution, optimizing our capital allocation, and advancing high-impact assets that drive sustainable growth and deliver innovative treatments to patients worldwide."

Industry Context

The biopharmaceutical industry continues to see strategic M&A activity, as evidenced by Fortress's successful divestitures of Checkpoint and Baergic, validating its diversified business model. The advancement of late-stage clinical assets like dotinurad, supported by significant Series A financing, reflects investor confidence in novel therapies for chronic conditions like gout. The challenges faced by CUTX-101 due to cGMP deficiencies highlight ongoing regulatory scrutiny in manufacturing, while the mixed results for anselamimab underscore the inherent risks in late-stage drug development, even for promising targets.

Comparison to Industry Standards

• The successful divestiture of Checkpoint Therapeutics to Sun Pharma and Baergic Bio to Axsome Therapeutics demonstrates effective asset monetization, aligning with industry trends of larger pharmaceutical companies acquiring promising clinical-stage or approved assets from smaller biotechs.
• The $205 million Series A financing for Crystalys Therapeutics to advance dotinurad in Phase 3 trials for gout is a substantial investment, indicating strong market confidence in its potential "best-in-class" safety and efficacy profile, comparable to significant funding rounds seen for other late-stage rare disease or specialty pharma assets.
• Journey Medical's Emrosi achieving expanded payer access to over 100 million commercial lives in the U.S. within a few months of launch is a strong commercial performance, often indicative of a well-executed market entry strategy and compelling clinical data in the dermatology space, potentially outperforming typical initial market penetration rates for new rosacea treatments.
• The FDA's Complete Response Letter (CRL) for CUTX-101 due to cGMP deficiencies, rather than efficacy or safety concerns, is a common regulatory hurdle in the pharmaceutical industry, emphasizing the critical importance of manufacturing quality and compliance for drug approval, a standard expectation across all therapeutic areas.
• AstraZeneca's anselamimab Phase III CARES program not meeting its primary endpoint, despite showing clinically meaningful improvement in a subgroup, reflects the high-risk nature of late-stage clinical trials, particularly in complex diseases like AL amyloidosis, where many promising candidates fail to demonstrate broad statistical significance.

Stakeholder Impact

• Shareholders: Positive impact due to increased revenue, return to net income profitability, successful asset monetizations (Checkpoint, Baergic), and potential future royalties/milestones. The increase in cash and cash equivalents also strengthens the company's financial position.
• Patients: Potential for new treatments advancing through clinical trials (dotinurad for gout, MB-101 for glioblastoma) and successful commercialization of Emrosi for rosacea. Delay for CUTX-101 for Menkes disease patients is a negative.
• Employees: Continued strategic progress and financial stability could provide job security and opportunities within the company and its subsidiaries.
• Partners (e.g., Sentynl, Sun Pharma, Axsome, Crystalys, AstraZeneca): Continued collaboration and potential for successful product development and commercialization. The CRL for CUTX-101 impacts Sentynl directly.

Next Steps

• Sentynl expects to resubmit the New Drug Application (NDA) for CUTX-101 shortly.
• AstraZeneca plans to submit the prespecified subgroup analysis from the CARES trials for anselamimab with regulatory authorities.
• Fortress intends to advance MB-101 in combination with MB-108 as a potential treatment option.
• Continue disciplined execution, optimizing capital allocation, and advancing high-impact assets.

Key Dates

Recommendation

Fortress Biotech has demonstrated a significant financial turnaround in Q3 2025, moving from a substantial net loss to a net income of $3.7 million, coupled with a 20.5% increase in net revenue. The successful divestitures of Checkpoint Therapeutics and Baergic Bio have not only generated immediate capital but also established long-term royalty and milestone payment streams, validating the company's diversified business model. The strong cash position of $86.2 million provides financial flexibility. Despite a regulatory delay for CUTX-101 due to manufacturing issues, the underlying efficacy and safety data were not questioned, and resubmission is expected shortly. The advancement of dotinurad into Phase 3 trials with significant external financing, and the successful commercialization of Emrosi, further strengthen the pipeline and commercial prospects. These factors collectively indicate a positive trajectory and strong potential for shareholder value creation.

Keywords

Biopharmaceutical, Q3 2025 Earnings, Drug Development, Gout Treatment, Rosacea Treatment, Menkes Disease, Oncology, Rare Diseases, CAR T-cell Therapy, Acquisitions, Royalties, Milestone Payments, FDA CRL, Clinical Trials, Fortress Biotech